SCHEMBL12501351

SCHEMBL12501351

CNC(=O)c1cc2cc(N)ccc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.55
HRH4 Q9H3N8 2/20 0.55
CYP2A6 P11509 1/20 0.50
KEAP1 Q14145 1/20 0.50
HDAC2 Q92769 1/20 0.48
KDM4E B2RXH2 3/20 0.47
GAA P10253 2/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPK1 P28482 1/20 0.47
TP53 P04637 1/20 0.47
POLB P06746 1/20 0.47
SYK P43405 1/20 0.46
PIN1 Q13526 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
KMT2A Q03164 1/20 0.45
CYP2D6 P10635 1/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19901352 0.83 HRH4 (0.51) HRH4CYP2A6KEAP1HDAC2KDM4E
SCHEMBL12848263 0.83 ALOX15 (0.58) ALOX15HRH4CYP2A6KEAP1HDAC2
SCHEMBL14845702 0.82 PIN1 (0.68) ALOX15HRH4HDAC2KDM4EALDH1A1
SCHEMBL12836981 0.82 FLT3 (0.67) ALOX15HRH4PDGFRBABL1KIT
SCHEMBL12862877 0.81 HRH4 (0.58) HRH4CYP2A6KEAP1HDAC2KDM4E
SCHEMBL1415238 0.81 KDM4E (0.61) ALOX15HRH4HDAC2KDM4EALDH1A1
SCHEMBL617200 0.81 XDH (0.59) HRH4CYP2A6KEAP1KDM4EGAA
SCHEMBL2760015 0.81 KDM4E (0.66) ALOX15HRH4HDAC2KDM4EALDH1A1
SCHEMBL12101200 0.81 ALOX15 (0.77) ALOX15HRH4NPC1RAB9ARXFP1
SCHEMBL7878275 0.80 HRH4 (0.48) ALOX15HRH4CYP2A6KEAP1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150216844-A1 SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES SYNTARGA B.V. (NL) 2015-08-06 US disclosed
EP-2668177-B1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INT (DE) 2014-10-22 EP disclosed
EP-2668177-B1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INT (DE) 2014-10-22 EP disclosed
US-8772305-B2 Substituted pyridinyl-pyrimidines and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-08 US disclosed
US-8772305-B2 Substituted pyridinyl-pyrimidines and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-08 US disclosed
US-8772305-B2 Substituted pyridinyl-pyrimidines and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-08 US disclosed
US-8680293-B2 Substituted CC-1065 analogs and their conjugates SYNTARGA B.V. (NL) 2014-03-25 US disclosed
EP-2668177-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2013-12-04 EP disclosed
EP-2173739-B1 SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES SYNTARGA BV (NL) 2013-07-31 EP disclosed
US-20130023502-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-24 US disclosed
US-20130023502-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-24 US disclosed
US-20130023502-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-24 US disclosed
WO-2012101013-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023502-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS ADORA1, P2RY1, P2RY11 ALOX15 694/4885HRH4 54/4885CYP2A6 98/4885
US-20150216844-A1 SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES PCNA, TOP1, TOP2B ALOX15 2925/4885HRH4 3040/4885CYP2A6 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.